COLUMBIA, Md., Mar 23, 2015 (BUSINESS WIRE) — Osiris Therapeutics, Inc.OSIR, -0.06% the leading cellular regenerative medicine company focused on developing and marketing products to treat conditions in wound care, orthopaedic and sports medicine markets announced today that Lode Debrabandere, Ph.D., President and Chief Executive Officer, is scheduled to present at the 3rd Annual Regen Med Investor Day on Wednesday, March 25, 2015 at 11:35 a.m. ET in New York City.
Organized by the Alliance for Regenerative Medicine (ARM) and co-hosted with Piper Jaffray, this one-day investor meeting provides institutional, strategic and venture investors with unique insight into the financing hypothesis for advanced therapies-based treatment and tools. The program includes clinical and commercial experts who are on-hand to address specific questions regarding the outlook for these products, as well as offer insight into how advanced therapies could impact the standard of care in key therapeutic areas. In addition to presentations by more than 30 leading companies from across the globe, the event includes dynamic, interactive panels featuring research analysts covering the space, key clinical opinion leaders and top company CEOs. These discussions will explore themes specific to cell and gene therapy such as commercialization, market access and pricing for breakthrough technologies, gene therapy delivery and upcoming milestones in the adoptive T-cell therapy space.
A live webcast of the presentation may be accessed through the Investors page of the Company’s website at www.Osiris.com. A replay of the webcast will be available for one week following the conference.
